Characterization of TauC3 antibody and demonstration of its potential to block tau propagation

The spread of neurofibrillary tangle (NFT) pathology through the human brain is a hallmark of Alzheimer’s disease (AD), which is thought to be caused by the propagation of “seeding” competent soluble misfolded tau. “TauC3”, a C-terminally truncated form of tau that is generated by caspase-3 cleavage at D421, has previously been observed in NFTs and has been implicated in tau toxicity. Here we show that TauC3 is found in the seeding competent high molecular weight (HMW) protein fraction of human AD brain. Using a specific TauC3 antibody, we were able to substantially block the HMW tau seeding activity of human AD brain extracts in an in vitro tau seeding FRET assay. We propose that TauC3 could contribute to the templated tau misfolding that leads to NFT spread in AD brains.

• Publication year

  2017

• Venue

  PLoS ONE

• Publication date

  2017-05-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1371/journal.pone.0177914PMID 28531180PMCID 5439699
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro.

  2017cited by this paper
• Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity.

  2016influential reference
• Co-expression of truncated and full-length tau induces severe neurotoxicity

  2016cited by this paper
• Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model.

  2016cited by this paper
• Seed‐competent high‐molecular‐weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients

  2016cited by this paper
• Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau

  2015cited by this paper
• Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain

  2015cited by this paper
• Phosphorylation of tau protein at sites Ser396–404 is one of the earliest events in Alzheimer's disease and Down syndrome

  2014cited by this paper
• Proteopathic tau seeding predicts tauopathy in vivo

  2014cited by this paper
• Distinct tau prion strains propagate in cells and mice and define different tauopathies.

  2014cited by this paper
• Physiological release of endogenous tau is stimulated by neuronal activity

  2013cited by this paper
• Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain.

  2011cited by this paper
• In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice

  2011cited by this paper
• Proteolytic processing of tau.

  2010influential reference
• Caspase activation precedes and leads to tangles

  2010influential reference
• Screening for Amyloid Aggregation by Semi-Denaturing Detergent-Agarose Gel Electrophoresis

  2008cited by this paper
• Purification of recombinant tau protein and preparation of Alzheimer-paired helical filaments in vitro.

  2005cited by this paper
• Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vector

  2004cited by this paper
• Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease

  2003cited by this paper
• Proapoptotic effects of tau cleavage product generated by caspase-3.

  2001cited by this paper
• Edinburgh Research Explorer Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport

  year unknowncited by this paper

• Development of a robust, physiologically relevant neuronal tau aggregation assay for tau-related drug discovery

  2025cites this paper
• Clearing truncated tau protein restores neuronal function and prevents microglia activation in tauopathy mice

  2025cites this paper
• Target the Heart: a new axis of Alzheimer’s disease prevention

  2025cites this paper
• MAPT mutations in amyotrophic lateral sclerosis: clinical, neuropathological and functional insights

  2025cites this paper
• Sleep-wake variation in body temperature regulates tau secretion and correlates with CSF and plasma tau

  2025cites this paper
• Target the Heart: A New Axis of Alzheimer’s Disease Prevention

  2025cites this paper
• Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP

  2024cites this paper
• Depletion of TDP-43 exacerbates tauopathy-dependent brain atrophy by sensitizing vulnerable neurons to caspase 3-mediated endoproteolysis of tau in a mouse model of Multiple Etiology Dementia

  2024cites this paper
• Sleep-wake body temperature regulates tau secretion in mice and correlates with CSF and plasma tau in humans

  2024cites this paper
• Oligomeric, phosphorylated, and truncated tau and spliceosome pathology within the entorhinal–hippocampal connectome across stages of Alzheimer's disease

  2023cites this paper
• Dual truncation of tau by caspase-2 accelerates its CHIP-mediated degradation.

  2023cites this paper
• Complicated Role of Post-translational Modification and Protease-Cleaved Fragments of Tau in Alzheimer’s Disease and Other Tauopathies

  2023cites this paper
• Unraveling the tau puzzle: a review of mechanistic targets and therapeutic interventions to prevent tau pathology in Alzheimer’s disease

  2023cites this paper
• Human tauopathy strains defined by phosphorylation in R1-R2 repeat domains of tau

  2023cites this paper
• Tau-targeting therapies for Alzheimer disease: current status and future directions

  2023cites this paper
• DnaJs are enriched in tau regulators.

  2023cites this paper
• Tau truncation in the pathogenesis of Alzheimer’s disease: a narrative review

  2023cites this paper
• Phosphorylation of a Cleaved Tau Proteoform at a Single Residue Inhibits Binding to the E3 Ubiquitin Ligase, CHIP

  2023cites this paper
• The E3 Ubiquitin Ligase, CHIP/STUB1, Inhibits Aggregation of Phosphorylated Proteoforms of Microtubule-associated Protein Tau (MAPT).

  2023cites this paper
• Caspase-cleaved tau is senescence-associated and induces a toxic gain of function by putting a brake on axonal transport

  2022influential citation
• Retromer deficiency in Tauopathy models enhances the truncation and toxicity of Tau

  2022cites this paper
• Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly.

  2021cites this paper
• iPSC-induced neurons with the V337M MAPT mutation are selectively vulnerable to caspase-mediated cleavage of tau and apoptotic cell death.

  2021cites this paper
• Possible Mechanisms of Tau Spread and Toxicity in Alzheimer’s Disease

  2021cites this paper
• Dendritic/Post-synaptic Tau and Early Pathology of Alzheimer’s Disease

  2021cites this paper
• Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons

  2021cites this paper
• Caspase-6-cleaved Tau fails to induce Tau hyperphosphorylation and aggregation, neurodegeneration, glial inflammation, and cognitive deficits

  2021cites this paper
• Caspase inhibition mitigates tau cleavage and neurotoxicity in iPSC-induced neurons with the V337M MAPT mutation

  2021cites this paper
• Tau Pathology in

  2021cites this paper
• Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein

  2020cites this paper
• Tau Prion-Like Propagation: State of the Art and Current Challenges.

  2019cites this paper
• Tau pathology in the medial temporal lobe of athletes with chronic traumatic encephalopathy: a chronic effects of neurotrauma consortium study

  2019cites this paper
• Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia

  2019cites this paper
• Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors.

  2019cites this paper
• Tau Propagation as a Diagnostic and Therapeutic Target for Dementia: Potentials and Unanswered Questions

  2019cites this paper
• Perspectives on drug discovery strategies based on IDPs

  2019cites this paper
• Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease.

  2018cites this paper
• Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain

  2018cites this paper
• Potential Neuroprotective Strategies for Concussion and Chronic Traumatic Encephalopathy

  2018cites this paper
• AD-Related N-Terminal Truncated Tau Is Sufficient to Recapitulate In Vivo the Early Perturbations of Human Neuropathology: Implications for Immunotherapy

  2018cites this paper
• Extracellular Monomeric and Aggregated Tau Efficiently Enter Human Neurons through Overlapping but Distinct Pathways

  2018cites this paper
• Prion-Like Propagation of Post-Translationally Modified Tau in Alzheimer’s Disease: A Hypothesis

  2018cites this paper
• Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways

  2017cites this paper
• New Insight into Alzheimer's Disease via Caspase 3-cleaved Tau: Pathogenic Role in Tau Oligomer Formation and Memory Deficits

  2017cites this paper